tradingkey.logo

60 Degrees Pharmaceuticals Inc

SXTP
0.689USD
-0.049-6.65%
收盤 12/24, 13:00美東報價延遲15分鐘
2.83M總市值
虧損本益比TTM

60 Degrees Pharmaceuticals Inc

0.689
-0.049-6.65%

關於 60 Degrees Pharmaceuticals Inc 公司

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

60 Degrees Pharmaceuticals Inc簡介

公司代碼SXTP
公司名稱60 Degrees Pharmaceuticals Inc
上市日期Jul 12, 2023
CEODow (Geoffrey S)
員工數量3
證券類型Ordinary Share
年結日Jul 12
公司地址1025 Connecticut Avenue Nw
城市WASHINGTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編20036
電話12023275422
網址https://60degreespharma.com/
公司代碼SXTP
上市日期Jul 12, 2023
CEODow (Geoffrey S)

60 Degrees Pharmaceuticals Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
22.79K
+46.19%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
15.82K
+79.40%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
5.27K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
4.54K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
234.00
--
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
234.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
234.00
--
Mr. Patrick Gaynes
Mr. Patrick Gaynes
Investor Relations Officer
Investor Relations Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
22.79K
+46.19%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
15.82K
+79.40%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
5.27K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
4.54K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
234.00
--
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
234.00
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Orca Capital GmbH
3.93%
Dow (Geoffrey S)
1.07%
Knight Therapeutics, Inc.
0.80%
DRW Securities, LLC
0.60%
Xu (Cheryl)
0.37%
其他
93.23%
持股股東
持股股東
佔比
Orca Capital GmbH
3.93%
Dow (Geoffrey S)
1.07%
Knight Therapeutics, Inc.
0.80%
DRW Securities, LLC
0.60%
Xu (Cheryl)
0.37%
其他
93.23%
股東類型
持股股東
佔比
Investment Advisor
4.53%
Individual Investor
1.70%
Corporation
0.80%
Investment Advisor/Hedge Fund
0.29%
Hedge Fund
0.07%
Bank and Trust
0.03%
其他
92.57%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
22
451.55K
11.00%
+385.44K
2025Q2
28
103.95K
3.22%
+2.41K
2025Q1
28
93.99K
6.38%
-12.96K
2024Q4
26
104.62K
14.10%
+11.58K
2024Q3
25
101.03K
25.05%
+54.30K
2024Q2
23
54.29K
27.13%
-3.10K
2024Q1
19
57.35K
31.08%
+1.78K
2023Q4
19
60.17K
63.69%
+30.80K
2023Q3
18
63.13K
66.75%
+44.65K

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Orca Capital GmbH
166.23K
4.05%
+166.23K
--
Jul 16, 2025
Dow (Geoffrey S)
22.79K
0.56%
+7.20K
+46.19%
Sep 12, 2025
Knight Therapeutics, Inc.
33.90K
0.83%
+14.67K
+76.26%
Sep 30, 2024
Xu (Cheryl)
15.82K
0.39%
+7.00K
+79.40%
Aug 26, 2025
Geode Capital Management, L.L.C.
12.52K
0.3%
+592.00
+4.96%
Jun 30, 2025
Miller (Tyrone)
5.27K
0.13%
--
--
Aug 26, 2025
Landon (Kristen)
4.54K
0.11%
--
--
Aug 26, 2025
Tower Research Capital LLC
2.60K
0.06%
+1.05K
+67.61%
Jun 30, 2025
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
公告日期
類型
比率
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1

常見問題

60 Degrees Pharmaceuticals Inc的前五大股東是誰?

60 Degrees Pharmaceuticals Inc的前五大股東如下:
Orca Capital GmbH
持有股份:166.23K
佔總股份比例:4.05%。
Dow (Geoffrey S)
持有股份:22.79K
佔總股份比例:0.56%。
Knight Therapeutics, Inc.
持有股份:33.90K
佔總股份比例:0.83%。
Xu (Cheryl)
持有股份:15.82K
佔總股份比例:0.39%。
Geode Capital Management, L.L.C.
持有股份:12.52K
佔總股份比例:0.30%。

60 Degrees Pharmaceuticals Inc的前三大股東類型是什麼?

60 Degrees Pharmaceuticals Inc 的前三大股東類型分別是:
Orca Capital GmbH
Dow (Geoffrey S)
Knight Therapeutics, Inc.

有多少機構持有60 Degrees Pharmaceuticals Inc(SXTP)的股份?

截至2025Q3,共有22家機構持有60 Degrees Pharmaceuticals Inc的股份,合計持有的股份價值約為451.55K,占公司總股份的11.00% 。與2025Q2相比,機構持股有所增加,增幅為7.78%。

哪個業務部門對60 Degrees Pharmaceuticals Inc的收入貢獻最大?

在--,--業務部門對60 Degrees Pharmaceuticals Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI